Energesis Pharmaceuticals

Energesis Pharmaceuticals is developing a new class of highly differentiated drugs that -- unlike marketed and development stage anti-obesity agents -- increase the body's energy expenditure, in order to address critical unmet needs in the fast-growing obesity and diabetes markets. Energesis is built to leverage small amounts of capital into high-impact, licensed clinical candidates. The company has already demonstrated proof of concept in animals with dramatic reductions in body weight, body fat, and blood sugar, increased energy expenditure, and no changes in lean mass or food intake. Moreover, the company’s lead product candidate produces synergistic weight loss with the market-leading obesity drugs. Energesis is now positioned to initiate a Phase 2 clinical study of EGS2632, a proprietary combination of two previously approved drugs.